Generation of highly pure fusions of colorectal carcinoma and antigen-presenting cells

Langenbeck's Archives of Surgery

Volumn 395, Issue 4, 2010, Pages 365-371

  Klier, Ulrike ^a   Maletzki, Claudia ^a   Klar, Ernst ^a   Linnebacher, Michael ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Cell fusion; Colorectal cancer; Immunotherapy; Tumor vaccine

Indexed keywords

CD40 ANTIGEN; GAMMA INTERFERON;

AGED; ANTIGEN PRESENTING CELL; ANTIGEN PURIFICATION; ARTICLE; B LYMPHOCYTE; CANCER CELL CULTURE; CELL FUSION; CELL LABELING; CELL SELECTION; COLON RESECTION; COLORECTAL CARCINOMA; DOSE RESPONSE; ENZYME LINKED IMMUNOSPOT ASSAY; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; HYBRID CELL; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE; COLORECTAL TUMOR; IMMUNOLOGY; TUMOR CELL LINE;

AGED, 80 AND OVER; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD40; B-LYMPHOCYTES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; HUMANS; HYBRID CELLS; MALE;

EID: 77954670980     PISSN: 14352443     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00423-010-0598-1     Document Type: Article

References (19)

1. Walden P (2000) Hybrid cell vaccination for cancer immunotherapy. Adv Exp Med Biol 465:347-354. doi:10.1007/0-306-46817-4-29
2. Phan V, Errington F, Cheong SC, Kottke T, Gough M, Altmann S, Brandenburger A, Emery S, Strome S, Bateman A, Bonnotte B, Melcher A, Vile R (2003) A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines. Nat Med 9(9):1215-1219. doi:10.1038/nm923 (Pubitemid 37173708)
3. Schultze JL, Grabbe S, von Bergwelt-Baildon MS (2004) DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy. Trends Immunol 25(12):659-664
4. Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, Hwu P (2003) CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 63(11):2836-2843. doi:10.1158/0008- 5472.CAN-03-3606
5. von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, Hirano N, Anderson KS, Butler MO, Xia Z, Zeng WY, Wucherpfennig KW, Nadler LM, Schultze JL (2002) Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 99(9):3319-3325
6. Gong J, Chen D, Kashiwaba M, Kufe D (1997) Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 3(5):558-561 (Pubitemid 27198656)
7. Homma S, Toda G, Gong J, Kufe D, Ohno T (2001) Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. J Gastroenterol 36(11):764-771
8. O'Rourke MG, Johnson M, Lanagan C, See J, Yang J, Bell JR, Slater GJ, Kerr BM, Crowe B, Purdie DM, Elliott SL, Ellem KA, Schmidt CW (2003) Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother 52(6):387-395. doi:10.1007/s00262-003-0375-x
9. Trefzer U, Herberth G, Wohlan K, Milling A, Thiemann M, Sherev T, Sparbier K, Sterry W, Walden P (2004) Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients. Int J Cancer 110(5):730-740. doi:10.1002/ijc.20191 (Pubitemid 38746032)
10. Li J, Holmes LM, Franek KJ, Burgin KE, Wagner TE, Wei Y (2001) Purified hybrid cells from dendritic cell and tumor cell fusions are superior activators of antitumor immunity. Cancer Immunol Immunother 50(9):456-462
11. Linnebacher M, Prall F, Klar E (2008) Establishment of colorectal xenograft models, corresponding cell lines and autologous B-LCLs. In: Chirurgisches Forum 2008. Springer, Berlin, pp 67-68
12. Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, Daley J, Delgado JC, Gribben JG, Nadler LM (1997) CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 100(11):2757-2765. doi:10.1172/JCI119822
13. Linnebacher M, Gebert J, Rudy W, Woerner S, Yuan YP, Bork P, von Knebel DM (2001) Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int J Cancer 93 (1):6-11
14. Norwood TH, Zeigler CJ, Martin GM (1976) Dimethyl sulfoxide enhances polyethylene glycol-mediated somatic cell fusion. Somatic Cell Genet 2(3):263-270
15. Jantscheff P, Spagnoli G, Zajac P, Rochlitz CF (2002) Cell fusion: an approach to generating constitutively proliferating human tumor antigen-presenting cells. Cancer Immunol Immunother 51 (7):367-375. doi:10.1007/s00262-002-0295-1 (Pubitemid 35002041)
16. Wei Y, Sticca RP, Holmes LM, Burgin KE, Li J, Williamson J, Evans L, Smith SJ, Stephenson JJ, Wagner TE (2006) Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses. Int J Oncol 28(3):585-593
17. Krause SW, Neumann C, Soruri A, Mayer S, Peters JH, Andreesen R (2002) The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. J Immunother 25(5):421-428
18. Guo GH, Chen SZ, Yu J, Zhang J, Luo LL, Xie LH, Su ZJ, Dong HM, Xu H, Wu LB (2008) In vivo anti-tumor effect of hybrid vaccine of dendritic cells and esophageal carcinoma cells on esophageal carcinoma cell line 109 in mice with severe combined immune deficiency. World J Gastroenterol 14(8):1167-1174
19. Valitutti S, Müller S, Cella M, Padovan E, Lanzavecchia A (1995) Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 375(6527):148-151. doi:10.1038/375148a0